Weizhou Zhang
- Cancer Research top 1%
- NF-κB Signaling Pathways 7
- Immunology top 2%
- Immune Cell Function and Interaction 9
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 11
- Cancer Cells and Metastasis 11
- Cancer-related Molecular Pathways 7
- Molecular Biology top 2%
- Ubiquitin and proteasome pathways 7
- Epigenetics and DNA Methylation 7
- PI3K/AKT/mTOR signaling in cancer 6
- Biomaterials top 5%
- Co-authors
- Ryan KolbMichael KarinNicholas BorcherdingFayyaz S. SutterwalaLu‐Hai WangGeorge Z. ChengAmy StrasnerJoseph L.‐K. Chan
- Cited by
- Cancer ResearchImmunologyOncology
- Journals
- Nature (1 paper)Science (1 paper)Proceedings of the National Academy of Sciences (2 papers)
- Partner nations
- United StatesChinaSouth Korea
In The Last Decade
Weizhou Zhang
105 papers receiving 5.0k citations
Hit Papers
Peers
Comparison fields: 5 of 145
- Cancer Research 1.1k
- Immunology 1.4k
- Oncology 1.8k
- Molecular Biology 2.8k
- Biomaterials 245
Countries citing papers authored by Weizhou Zhang
This map shows the geographic impact of Weizhou Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weizhou Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weizhou Zhang more than expected).
Fields of papers citing papers by Weizhou Zhang
This network shows the impact of papers produced by Weizhou Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weizhou Zhang. The network helps show where Weizhou Zhang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Weizhou Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 14 | |
| 3 | 2024 | 6 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 20 | |
| 7 | 2023 | 0 | |
| 8 | 2022 | 1 | |
| 9 | 2021 | 19 | |
| 10 | 2021 | 42 | |
| 11 | 2020 | 11 | |
| 12 | 2019 | 88 | |
| 13 | 2016 | 187 | |
| 14 | 2016 | 63 | |
| 15 | 2015 | 46 | |
| 16 | 2013 | 1 | |
| 17 | 2013 | 8 | |
| 18 | 2008 | 179 | |
| 19 | 2007 | 458 | |
| 20 | 2002 | 36 |
About Weizhou Zhang
Weizhou Zhang is a scholar working on Oncology, Immunology and Cancer Research, having authored 111 papers that have together received 5.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Cancer Cells and Metastasis (11 papers), Immune Cell Function and Interaction (9 papers), Ubiquitin and proteasome pathways (7 papers), Cancer-related Molecular Pathways (7 papers), NF-κB Signaling Pathways (7 papers), Epigenetics and DNA Methylation (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Cancer Research (1.1k citations), Immunology (1.4k citations) and Oncology (1.8k citations). Weizhou Zhang has collaborated with scholars based in United States, China and South Korea. Frequent co-authors include Ryan Kolb, Michael Karin, Nicholas Borcherding, Fayyaz S. Sutterwala, Lu‐Hai Wang, George Z. Cheng, Amy Strasner, Joseph L.‐K. Chan, Wei Phin Tan and Jin Q. Cheng. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.